Drugs

The Platinum Healthcare LLC

FDA issued a warning letter to The Platinum Healthcare LLC (Pulaski, TN, United States) on Oct 1, 2026, citing 21 CFR 201.128. Subject: Unapproved New Drugs.

From the letter: ““Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Gonorrhea miasm.””

Pulaski, TN, United StatesIssued Oct 1, 2026Posted Oct 6, 2026No close-out recorded

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
3 findings · 2 issue types
Response due
Fifteen (15) business days of receipt
FDA asks for
4 actions
Named as possible actions
Seizure, injunction
Issued by
Center for Drug Evaluation and Research
Published status
No close-out recorded

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01Labeling, claims & marketing · 21 CFR 201.128Sycosis product labeling claims treatment of gonorrhea miasm, indicating drug intended use.
“Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Gonorrhea miasm.”
02Labeling, claims & marketing · 21 CFR 201.128Syphillinum product labeling claims treatment of syphilis miasm, indicating drug intended use.
“Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Syphilis miasm.”
03Registration, listing & premarketProducts are unapproved new drugs marketed without FDA-approved applications.
No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products.

What FDA requested

  • Provide specific steps taken to correct the violations
  • Explain each step being taken to prevent recurrence
  • Submit copies of related documentation
  • Include information demonstrating products are not in violation

FDA Warning Letter

24 paragraphs · 7 sections

Text as published on FDA.gov, retrieved Nov 4, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

DatedOctober 1, 2026
Reference735147
AddressedJamey Hagan

1Introduction

2 paragraphs

This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https://platinumwellnesscenter.org/, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.

As discussed below, the “Sycosis” and “Syphillinum” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and/or their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.

2FDA Review

2 paragraphs

Violations were identified and documented during a review of your website https://platinumwellnesscenter.org/ in July 2026. Based on our review, “Sycosis” and “Syphillinum” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.

3Violations of the Federal Food, Drug, and Cosmetic Act

1 paragraph

The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.

4Unapproved New Drug Violations

1 paragraph

Based on a review of your website, “Sycosis” and “Syphillinum” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:

5Sycosis

2 paragraphs

On the webpage https://platinumwellnesscenter.org/store/sycosis/:

“Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Gonorrhea miasm.”

6Syphillinum

4 paragraphs

On the webpage https://platinumwellnesscenter.org/store/syphilinum/:

“Oral antigen for desensitizing and stimulating the body’s immune defense mechanism against problems caused by the Syphilis miasm.”

“Sycosis” and “Syphillinum” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

We recognize that your “Sycosis” and “Syphillinum” products are labeled as homeopathic drugs with active ingredient(s) measured in homeopathic strengths. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.

7Conclusion

3 paragraphs

As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.

Response requested

Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “735147” in the subject line of the email.

Please note FDA posts warning letters on www.fda.gov.

Sincerely,/S/

Tina Smith, M.S.Captain, U.S. Public Health ServiceDirectorOffice of Unapproved Drugs and Labeling ComplianceOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 10, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

Regulations

Issue types

Record details

Issuing center
Center for Drug Evaluation and Research
Issuing office
Center for Drug Evaluation and Research
Location
Pulaski, TN, United States
Letter posted date
Oct 6, 2026
Letter issue date
Oct 1, 2026
Addressed to
CEO
Inspection dates
Not recorded
Response window
15 business days after receipt of this letter
Read the source clause
Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter.
Record length
888 words · 0 recorded redactions
Published status
No published close-out
FDA reference
735147
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 20, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,711 lettersFind letters like this →
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.